Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways.
Skadborg SK, Maarup S, Draghi A, Borch A, Hendriksen S, Mundt F, Pedersen V, Mann M, Christensen IJ, Skjøth-Ramussen J, Yde CW, Kristensen BW, Poulsen HS, Hasselbalch B, Svane IM, Lassen U, Hadrup SR.
Skadborg SK, et al. Among authors: maarup s.
Cancer Immunol Res. 2024 Sep 3;12(9):1202-1220. doi: 10.1158/2326-6066.CIR-23-0959.
Cancer Immunol Res. 2024.
PMID: 38885356
Free PMC article.